Universidad Peruana Cayetano Heredia

Detection of Taenia solium taeniasis coproantigen is an early indicator of treatment failure for taeniasis.

Mostrar el registro sencillo del ítem

dc.contributor.author Bustos Palomino, Javier Arturo
dc.contributor.author Rodriguez, Silvia
dc.contributor.author Jimenez, Juan A.
dc.contributor.author Moyano, Luz M.
dc.contributor.author Castillo Berrios, Yesenia
dc.contributor.author Ayvar, Viterbo
dc.contributor.author Allan, James C.
dc.contributor.author Craig, Philip S.
dc.contributor.author Gonzalez Zariquiey, Armando Emiliano
dc.contributor.author Gilman, Robert Hugh
dc.contributor.author Tsang, Victor C. W.
dc.contributor.author García Lescano, Héctor Hugo
dc.date.accessioned 2022-01-18T19:26:53Z
dc.date.available 2022-01-18T19:26:53Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/10994
dc.description.abstract Taenia solium causes taeniasis and cysticercosis, a zoonotic complex associated with a significant burden of epilepsy in most countries. Reliable diagnosis and efficacious treatment of taeniasis are needed for disease control. Currently, cure can be confirmed only after a period of at least 1 month, by negative stool microscopy. This study assessed the performance of detection by a coproantigen enzyme-linked immunosorbent assay (CoAg-ELISA) for the early evaluation of the efficacy of antiparasitic treatment of human T. solium taeniasis. We followed 69 tapeworm carriers who received niclosamide as standard treatment. Stool samples were collected on days 1, 3, 7, 15, 30, and 90 after treatment and were processed by microscopy and CoAg-ELISA. The efficacy of niclosamide was 77.9% (53/68). Thirteen patients received a second course of treatment and completed the follow-up. CoAg-ELISA was therefore evaluated for a total of 81 cases (68 treatments, 13 retreatments). In successful treatments (n = 64), the proportion of patients who became negative by CoAg-ELISA was 62.5% after 3 days, 89.1% after 7 days, 96.9% after 15 days, and 100% after 30 days. In treatment failures (n = 17), the CoAg-ELISA result was positive for 70.6% of patients after 3 days, 94.1% after 7 days, and 100% after 15 and 30 days. Only 2 of 17 samples in cases of treatment failure became positive by microscopy by day 30. The presence of one scolex, but not multiple scolices, in posttreatment stools was strongly associated with cure (odds ratio [OR], 52.5; P < 0.001). CoAg-ELISA is useful for the assessment of treatment failure in taeniasis. Early assessment at day 15 would detect treatment failure before patients become infective. en_US
dc.language.iso eng
dc.publisher American Society for Microbiology
dc.relation.ispartofseries Clinical and Vaccine Immunology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Animals en_US
dc.subject parasite antigen en_US
dc.subject drug efficacy en_US
dc.subject follow up en_US
dc.subject Follow-Up Studies en_US
dc.subject antiparasitic agent en_US
dc.subject Enzyme-Linked Immunosorbent Assay en_US
dc.subject Time Factors en_US
dc.subject Feces en_US
dc.subject Prospective Studies en_US
dc.subject parasite identification en_US
dc.subject sensitivity and specificity en_US
dc.subject outcome assessment en_US
dc.subject enzyme linked immunosorbent assay en_US
dc.subject Taenia solium en_US
dc.subject taeniasis en_US
dc.subject niclosamide en_US
dc.subject Anthelmintics en_US
dc.subject feces analysis en_US
dc.subject Antigens, Helminth en_US
dc.subject predictive value en_US
dc.subject drug treatment failure en_US
dc.subject Treatment Failure en_US
dc.subject antigen detection en_US
dc.subject clinical assessment tool en_US
dc.subject clinical indicator en_US
dc.subject Clinical Laboratory Techniques en_US
dc.subject Drug Monitoring en_US
dc.subject Early Diagnosis en_US
dc.subject Niclosamide en_US
dc.subject Parasitology en_US
dc.subject patient assessment en_US
dc.subject scolex en_US
dc.subject Taeniasis en_US
dc.title Detection of Taenia solium taeniasis coproantigen is an early indicator of treatment failure for taeniasis. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1128/CVI.05428-11
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.03
dc.relation.issn 1556-679X


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas